Important Information

This section of the website (the “Microsite”) of Mereo BioPharma Group plc (the “Company”) has been prepared solely for your information and for the purpose of providing background information on the Company, its business, the upcoming general meeting of the Company’s shareholders, and the industry in which the Company operates or any particular aspect thereof. For further information, please see the shareholder circular published by the Company in connection with the General Meeting which is available at www.mereobiopharma.com/GeneralMeeting2022 or at sec.gov.

The information contained in the Microsite has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the Microsite and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in the Microsite is subject to verification, correction, completion and change without notice. In making available the Microsite, none of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update the information contained in the Microsite or to provide the recipient with access to any additional information that may arise in connection with it. Accordingly, undue reliance should not be placed on any of the data contained in the Microsite.

Forward-Looking Statements

The Microsite and the information in it contain “forward-looking statements.” All statements other than statements of historical fact are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events, including, but not limited to, statements regarding future clinical development, efficacy, safety and therapeutic potential of clinical product candidates, including expectations as to reporting of data, conduct and timing and potential future clinical activity and milestones and expectations regarding the initiation, design and reporting of data from clinical trials. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its latest Annual Report on Form 20-F, reports on Form 6-K and other documents furnished or filed from time to time by the Company with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. The Microsite and the information in it also contain estimates, projections and other information concerning the Company’s business and the markets for the Company’s product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.


Working with partners

Working With You Images Partners 1

We create valuable opportunities for partners by combining extensive clinical experience, deep expertise in rare diseases and tumors, and business acumen to strategically identify molecules that are worth developing further.

Our partners have a mission-critical role to play – providing the resources, skills and perspective that is integral to the development of therapies.

Changing the course of rare diseases together

"We seek to leverage the strong development and regulatory progress Mereo has already made to continue the development of navicixizumab and ultimately make this investigational therapy available to patients as quickly as possible.”

Laura E. Benjamin, Ph.D., Chief Executive Officer of OncXerna

Partner updates

Opportunities to join our mission

Mereo actively seeks partners with aligning strategic priorities and values to ensure that we can unlock the full potential of our pipeline for all stakeholders, particularly patients.

We currently have three clinical-stage programs with partnering opportunities.


Navicixizumab (OMP305B83)

For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.


Acumapimod (BCT197)

For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).


Leflutrozole (BGS649)

For the potential treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).

Our current partners

Novartis Logo

Mereo acquired a portfolio in July 2015 including Setrusumab, Acumapimod and Leflutrozole.

Astraxeneca Logo

Mereo in-licensed Alvelestat from AstraZeneca In October 2017.

Ultragenyx Logo
Ultragenyx Pharmaceutical, Inc.

In December 2020, Mereo entered a collaboration and license for the development and co-commercialization of Setrusumab.

Onexerna Logo
OncXerna Therapeutics

Mereo out-licensed Navicixizumab to OncXerna in January 2020.


Let's talk

Please do not send any confidential information using the form. We look forward to hearing from you.


Get In Touch

Reason for contact

  • General Enquiries
  • Partnering Enquiries
  • Careers
  • Other

Your information will be processed in line with our Privacy Notice